TopoTarget (OMX: TOPO) is a biotech company dedicated to finding "Answers for cancer". The Company is focused on the development and commercialisation of improved treatments for cancer patients, and other cancer-related disorders. TopoTarget has a marketed product in both Europe and the US and a broad late stage clinical pipeline containing nine products.
TopoTarget was formed in 2000 in Copenhagen, and is headquartered in Denmark with subsidiaries in the US, Switzerland, Germany and the UK. The company completed a successful IPO on the OMX Nordic Exchange in Copenhagen in 2005. TopoTarget was founded and is run by clinical cancer specialists, and combines years of hands-on clinical experience with an in-depth understanding of the molecular mechanisms of cancer.